Justin Antony

Dr. Justin Antony

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Neurochemistry International
Verified
Journal Article
Closed access
PRPrashantha B R
Prashantha B R
AKAshwini Prem Kumar
Ashwini Prem Kumar
JJJincy A. Jose
Jincy A. Jose
PPP. Prabitha
P. Prabitha
SYS. Yuvaraj
S. Yuvaraj
JAJustin Antony
Justin Antony

22 March 2016 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Closed access
PDF file
JNJawahar Natarajan
Jawahar Natarajan
MBMahendran Baskaran
Mahendran Baskaran
LHLireni C. Humtsoe
Lireni C. Humtsoe
VRVadivelan Ramachandran
Vadivelan Ramachandran
JAJustin Antony
Justin Antony
Olanzapine (OLZ) is a typical anti-psychotic drug, which is highly lipophilic in nature, belongs to Biopharmaceutical Classification System (BCS) class II category. Though OLZ is an effective agent in the treatment of Schizophrenia, but it exhibits poor bioavailability (57%) due to extensive first-pass metabolism resulted in high dose is required to achieve therapeutic concentration in brain. Emerging evidences are indicating that high dose administration of OLZ may cause Extrapyramidal symptoms (EPS) in the psychotic patients. Hence, the present study is designed to develop Olanzapine solid lipid (OLZ-SLNs) using minimal dose of OLZ thereby enhancing the brain efficacy as well as to reduce the side effects associated with OLZ. OLZ-SLNs have been prepared by “solvent diffusion method” using lipids, such as glyceryl monostearate (GMS), tripalmitin (TP), Tween 80, and Stearyl amine as positive charge inducer. The prepared OLZ-SLNs were subjected to particle size analysis, zeta potential, and poly dispersity index measurement by using Malvern Zetasizer. Pharmacokinetics assessments of OLZ-SLNs were carried in conscious male Wistar rats through intravenous administration. Results have shown that average particle size and zeta potential of SLNs of GMS and TP were ranged from 165.1 ± 2.2 to 110.5 ± 0.5 and 35.29 ± 1.2 and 66.50 ± 0.7 mV, respectively. Relative bioavailability of OLZ in the brain was increased up to 23-fold and clearance was decreased when OLZ-SLNs while administrated intravenously. The area under the curve (AUC) and mean residence time (MRT) of OLZ-SLNs in brain were higher than OLZ suspension. These results indicate that SLNs are a promising drug delivery for OLZ. It may be an effective tool to enhance the bioavailability of OLZ in the brain with less dose administration, which could reduce the EPS associated with OLZ.

1 October 2015 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
PSPrathab Balaji Saravanan
Prathab Balaji Saravanan
CCC. Vijay Chand
C. Vijay Chand
JAJustin Antony
Justin Antony
MRM. Ramanathan
M. Ramanathan

1 July 2014 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
JAJustin Antony
Justin Antony
MSM. Sathishkumar
M. Sathishkumar
ASA. Sudheer
A. Sudheer
SSS. Shanthakumari
S. Shanthakumari
MRM. Ramanathan
M. Ramanathan

28 November 2019 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
JAJustin Antony
Justin Antony
SMSubhankar Mandal
Subhankar Mandal
PPP. Prabitha
P. Prabitha
SDS. Dhivya
S. Dhivya
SYS. Yuvaraj
S. Yuvaraj
PRPrashantha B R
Prashantha B R

2 July 2021 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AKAshwini Prem Kumar
Ashwini Prem Kumar
PPPrabitha P
Prabitha P
PRPrashantha B R
Prashantha B R
VJVictoria Jeyarani
Victoria Jeyarani
SDS.P. Dhanabal
S.P. Dhanabal
JAJustin Antony
Justin Antony
The transcriptional factor PPAR-γ belongs to the nuclear receptor family, which has become a potential therapeutic target for several neurodegenerative diseases and metabolic disorders. Interestingly, PPAR-γ has been reported to have beneficial effects in various chronic neurological conditions via upregulation of its transcriptional co-activator PGC-1α and followed by regulation of multiple molecular events. Although several factors contribute to the progression of neurodegeneration, the dysfunction of PGC-1α expression is primarily interlinked with the pathogenesis of major neurodegenerative diseases. This review gives an insight that ligand-dependent activation of PPAR-γ by glitazones could initiate the structural conformational changes of the secondary proteins, thus recruiting the PGC-1α to form a stable regulatory complex that hampers the various molecular pathways contributing to neurodegeneration. The promising outcomes of the preliminary in silico studies included in this review support that PPAR-γ dependent activation of central PGC-1α signaling by novel glitazones is an encouraging strategy to enhance the oxy-radicals detoxifying system, antiinflammatory responses, and mitochondrial biogenesis required for neuroprotection in various neurodegenerative conditions.